Technical Analysis for TIL - Instil Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical TIL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -9.83% | |
| Fell Below 50 DMA | Bearish | -9.83% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | -9.83% | |
| Below Lower BB | Weakness | -9.83% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 10% | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 7 hours ago |
| Down 5% | about 7 hours ago |
| Down 1 ATR | about 7 hours ago |
| Down 3% | about 8 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Cancer Immunotherapy Non Small Cell Lung Cancer Melanoma Cell Therapy Cervical Cancer Lymphocytes Cutaneous Squamous Cell Carcinoma Head And Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Therapies For The Treatment Of Patients With Cancer Tumor Infiltrating Lymphocytes
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Oncology Cancer Immunotherapy Non Small Cell Lung Cancer Melanoma Cell Therapy Cervical Cancer Lymphocytes Cutaneous Squamous Cell Carcinoma Head And Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Therapies For The Treatment Of Patients With Cancer Tumor Infiltrating Lymphocytes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.49 |
| 52 Week Low | 14.42 |
| Average Volume | 387,961 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 18.22 |
| 20-Day Moving Average | 19.21 |
| 10-Day Moving Average | 18.76 |
| Average True Range | 1.19 |
| ADX | 22.05 |
| +DI | 19.10 |
| -DI | 27.56 |
| Chandelier Exit (Long, 3 ATRs) | 17.29 |
| Chandelier Exit (Short, 3 ATRs) | 19.80 |
| Upper Bollinger Bands | 20.90 |
| Lower Bollinger Band | 17.52 |
| Percent B (%b) | -0.33 |
| BandWidth | 17.59 |
| MACD Line | -0.07 |
| MACD Signal Line | 0.22 |
| MACD Histogram | -0.2867 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.41 | ||||
| Resistance 3 (R3) | 19.67 | 18.95 | 18.91 | ||
| Resistance 2 (R2) | 18.95 | 18.19 | 18.81 | 18.74 | |
| Resistance 1 (R1) | 17.68 | 17.72 | 17.32 | 17.42 | 18.58 |
| Pivot Point | 16.96 | 16.96 | 16.78 | 16.82 | 16.96 |
| Support 1 (S1) | 15.69 | 16.20 | 15.33 | 15.43 | 14.26 |
| Support 2 (S2) | 14.97 | 15.73 | 14.83 | 14.10 | |
| Support 3 (S3) | 13.70 | 14.97 | 13.93 | ||
| Support 4 (S4) | 13.44 |
